Stock Track | Labcorp Soars 5.19% in Pre-Market on Strong Q4 Earnings and Upbeat 2026 Guidance

Stock Track

Feb 17

Labcorp Holdings Inc's stock surged 5.19% during pre-market trading on Tuesday, following the release of its fourth-quarter 2025 financial results and 2026 outlook.

The company reported adjusted earnings of $4.07 per share for the quarter, exceeding analyst estimates of around $3.89 to $3.94. While quarterly revenue of $3.52 billion slightly missed expectations, it represented a year-over-year increase. The diagnostics segment, a key growth driver, saw revenue rise 5.5% during the period.

Investors reacted positively to Labcorp's forecast for fiscal 2026, which calls for adjusted earnings per share between $17.55 and $18.25. The midpoint of this range is above the average analyst estimate. The company also expects revenue between $14.61 billion and $14.79 billion, citing robust demand for diagnostic tests and benefits from hospital laboratory management agreements as factors supporting continued growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1104738964"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104738964\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104738964?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104738964","market":"sg","top_or_hot":-1,"title":"Stock Track | Labcorp Soars 5.19% in Pre-Market on Strong Q4 Earnings and Upbeat 2026 Guidance","media":"Stock Track","content":"<p>Labcorp Holdings Inc's stock surged 5.19% during pre-market trading on Tuesday, following the release of its fourth-quarter 2025 financial results and 2026 outlook.</p><p>The company reported adjusted earnings of $4.07 per share for the quarter, exceeding analyst estimates of around $3.89 to $3.94. While quarterly revenue of $3.52 billion slightly missed expectations, it represented a year-over-year increase. The diagnostics segment, a key growth driver, saw revenue rise 5.5% during the period.</p><p>Investors reacted positively to Labcorp's forecast for fiscal 2026, which calls for adjusted earnings per share between $17.55 and $18.25. The midpoint of this range is above the average analyst estimate. The company also expects revenue between $14.61 billion and $14.79 billion, citing robust demand for diagnostic tests and benefits from hospital laboratory management agreements as factors supporting continued growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Labcorp Soars 5.19% in Pre-Market on Strong Q4 Earnings and Upbeat 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Labcorp Soars 5.19% in Pre-Market on Strong Q4 Earnings and Upbeat 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-17 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Labcorp Holdings Inc's stock surged 5.19% during pre-market trading on Tuesday, following the release of its fourth-quarter 2025 financial results and 2026 outlook.</p><p>The company reported adjusted earnings of $4.07 per share for the quarter, exceeding analyst estimates of around $3.89 to $3.94. While quarterly revenue of $3.52 billion slightly missed expectations, it represented a year-over-year increase. The diagnostics segment, a key growth driver, saw revenue rise 5.5% during the period.</p><p>Investors reacted positively to Labcorp's forecast for fiscal 2026, which calls for adjusted earnings per share between $17.55 and $18.25. The midpoint of this range is above the average analyst estimate. The company also expects revenue between $14.61 billion and $14.79 billion, citing robust demand for diagnostic tests and benefits from hospital laboratory management agreements as factors supporting continued growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LH","symbol_name":"徕博科","start_time":0,"source_url":"","article_id":"1104738964","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104738964","pubTimestamp":1771333392,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Labcorp Holdings Inc's stock surged 5.19% during pre-market trading on Tuesday, following the release of its fourth-quarter 2025 financial results and 2026 outlook.The company reported adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LH":"徕博科"},"translate_title":"股票追踪|Labcorp盘前飙升5.19%，得益于强劲的第四季度盈利和乐观的2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1},"content_text":"Labcorp Holdings Inc's stock surged 5.19% during pre-market trading on Tuesday, following the release of its fourth-quarter 2025 financial results and 2026 outlook.The company reported adjusted earnings of $4.07 per share for the quarter, exceeding analyst estimates of around $3.89 to $3.94. While quarterly revenue of $3.52 billion slightly missed expectations, it represented a year-over-year increase. The diagnostics segment, a key growth driver, saw revenue rise 5.5% during the period.Investors reacted positively to Labcorp's forecast for fiscal 2026, which calls for adjusted earnings per share between $17.55 and $18.25. The midpoint of this range is above the average analyst estimate. The company also expects revenue between $14.61 billion and $14.79 billion, citing robust demand for diagnostic tests and benefits from hospital laboratory management agreements as factors supporting continued growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}